|
1
|
Visa L, Jimenez-Fonseca P, Martinez EA,
Hernández R, Custodio A, Garrido M, Viudez A, Buxo E, Echavarria I,
Cano JM, et al: Efficacy and safety of chemotherapy in older versus
non-older patients with advanced gastric cancer: A real-world data,
non-inferiority analysis. J Geriatr Oncol. 9:254–264. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suzuki H and Mori H: World trends for H.
pylori eradication therapy and gastric cancer prevention strategy
by H. pylori test-and-treat. J Gastroenterol. 53:354–361. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carmona-Bayonas A, Jimenez-Fonseca P,
Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria
I, Lacalle A, Visa L, Palomo Rodríguez A, et al:
Anthracycline-based triplets do not improve the efficacy of
platinum-fluoropyrimidine doublets in first-line treatment of
advanced gastric cancer: Real-world data from the AGAMEMON National
Cancer Registry. Gastric Cancer. 21:96–105. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun N, Sun Q, Liu Q, Zhang T, Zhu Q, Wang
W, Cao M and Zang QI: α-fetoprotein-producing gastric carcinoma: A
case report of a rare subtype and literature review. Oncol Lett.
11:3101–3104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tian Q, Zeng J, Tao X, Zhang Z, Zhou X and
Wang Y: Clinical pathology of metastatic gastric carcinoma to the
breast: A report of two cases and a review of literature. Oncol
Lett. 11:3081–3084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrioli R, Roviello G, Zanotti L,
Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D
and Generali D: Epirubicin-based compared with docetaxel-based
chemotherapy for advanced gastric carcinoma: A systematic review
and meta-analysis. Crit Rev Oncol Hematol. 102:82–88. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shan B, Shan L, Morris D, Golani S and
Saxena A: Systematic review on quality of life outcomes after
gastrectomy for gastric carcinoma. J Gastrointest Oncol. 6:544–560.
2015.PubMed/NCBI
|
|
8
|
Bollschweiler E, Berlth F, Baltin C, Mönig
S and Hölscher AH: Treatment of early gastric cancer in the Western
World. World J Gastroenterol. 20:5672–5678. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshikawa T, Aoyama T, Hayashi T, Kuwabara
H, Mikayama Y, Ogata T, Cho H and Tsuburaya A: Neoadjuvant
chemotherapy for gastric cancer-evidence from the world and future
strategy in Japan. Gan To Kagaku Ryoho. 39:866–870. 2012.(In
Japanese). PubMed/NCBI
|
|
10
|
Kocáková I, Vetchá H, Soumarová R and
Vyzula R: Role of adjuvant chemoradiotherapy in the treatment of
gastric carcinoma. Cas Lek Cesk. 142 Suppl 1:S26–S28. 2003.(In
Czech).
|
|
11
|
Sher DJ: Neoadjuvant chemoradiotherapy for
stage III Non-small cell lung cancer. Front Oncol. 7:2812017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Sluis FJ, van Westreenen HL, van
Etten B, van Leeuwen BL and de Bock GH: Pretreatment identification
of patients likely to have pathologic complete response after
neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal
Dis. 33:149–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun Y, Zhang Y, Wu X, Lin H, Lu X, Huang
Y, Xu Z, Huang S, Wang X and Chi P: Prognostic significance of
neoadjuvant rectal score in locally advanced rectal cancer after
neoadjuvant chemoradiotherapy and construction of a prediction
model. J Surg Oncol. 117:737–744. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rino Y, Yukawa N, Wada N, Suzuki M,
Murakami H, Yamada T, Nakayama H, Yamamoto N, Sato T, Yamada R, et
al: Phase II study of S-1 monotherapy as a First-line, combination
therapy of S-1 plus cisplatin as a Second-line, and weekly
paclitaxel monotherapy as a Third-line therapy in patients with
advanced gastric carcinoma: Phase II study of S-1, S-1 plus
cisplatin, and weekly paclitaxel in patients with advanced gastric
carcinoma. Clin Med Oncol. 2:375–383. 2008.PubMed/NCBI
|
|
15
|
Chen JL, Zhu JS, Hong J, Chen MX, Lu JL,
Chen WX, Shen B, Zhu ZM and Chen NW: Effect of
2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid
in combination with carboplatin on gastric carcinoma growth in
vivo. World J Gastroenterol. 13:509–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fukuda K, Tsujitani S, Maeta Y, Yamaguchi
K, Ikeguchi M and Kaibara N: The expression of RCAS1 and tumor
infiltrating lymphocytes in patients with T3 gastric carcinoma.
Gastric Cancer. 5:220–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koyama S: Differential expression of
intracellular apoptotic signaling molecules in tumor and
tumor-infiltrating lymphocytes during development of invasion
and/or metastasis of gastric carcinoma. Dig Dis Sci. 48:2290–2300.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haas M, Buttner M, Rau TT, Fietkau R,
Grabenbauer GG and Distel LV: Inflammation in gastric
adenocarcinoma of the cardia: How do EBV infection, Her2
amplification and cancer progression influence tumor-infiltrating
lymphocytes? Virchows Arch. 458:403–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mlecnik B, Tosolini M, Kirilovsky A,
Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman
WH, Pagès F and Galon J: Histopathologic-based prognostic factors
of colorectal cancers are associated with the state of the local
immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Waddell T, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D: Gastric cancer: ESMO-ESSO-ESTRO
clinical practice guidelines for diagnosis, treatment and
follow-up. Eur J Surg Oncol. 40:584–591. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Szurek E, Cebula A, Wojciech L, Pietrzak
M, Rempala G, Kisielow P and Ignatowicz L: Differences in
expression level of helios and Neuropilin-1 do not distinguish
thymus-derived from extrathymically-induced CD4+Foxp3+ regulatory T
cells. PLoS One. 10:e01411612015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brandt D, Sergon M, Abraham S, Mäbert K
and Hedrich CM:
TCR+CD3+CD4−CD8−
effector T cells in psoriasis. Clin Immunol. 181:51–59. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Shen Y, Zhu H, Zhao Y, Li Z, Qiu
M, Li Q, Gou H, Yang Y, Cao D, et al: A phase II trial of
concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and
leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy
and D2 lymph node dissection. Gastric Cancer. 19:245–254. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Li G, Zhang Y, Bai S, Xu F, Wei Y
and Gong Y: Single-arc volumetric-modulated arc therapy (sVMAT) as
adjuvant treatment for gastric cancer: Dosimetric comparisons with
three-dimensional conformal radiotherapy (3D-CRT) and
intensity-modulated radiotherapy (IMRT). Med Dosim. 38:395–400.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Papadimitriou K, Vassiliou V, Kountourakis
P, Polyviou P, Andreopoulos D and Papamichael D: Adjuvant
chemoradiotherapy (CRT) for high-risk gastric cancer (GC) patients:
Single-center experience using infusional 5-fluorouracil (5FU) and
radiotherapy (RT). Med Oncol. 29:2716–2717. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Plosker GL and Hurst M: Paclitaxel: A
pharmacoeconomic review of its use in non-small cell lung cancer.
Pharmacoeconomics. 19:1111–1134. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li L, Wen XZ, Bu ZD, Cheng XJ, Xing XF,
Wang XH, Zhang LH, Guo T, Du H, Hu Y, et al: Paclitaxel enhances
tumoricidal potential of TRAIL via inhibition of MAPK in resistant
gastric cancer cells. Oncol Rep. 35:3009–3017. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Y, Liu N, Xiong SD, Zheng YJ and Chu
YW: CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is
independent of toll-like receptor 4. Scand J Immunol. 73:301–308.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Pang L and Feng J: A phase II
study of etoposide, doxorubicin, and carboplatin in the treatment
of advanced gastric cancer. Am J Clin Oncol. 25:71–75. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mobayed M, Heilbrun LK, Shields AF,
Washington T, Venkatramanamoorthy R, Philip PA and El-Rayes BF:
Safety and feasibility of carboplatin and paclitaxel followed by
fluoropyrimidine analogs and radiation as adjuvant therapy for
gastric cancer. Case Rep Oncol. 2:220–228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu X, Yang L, Yao D, Wu X, Li J, Liu X,
Deng L, Huang C, Wang Y, Li D and Liu J: Tumor antigen-specific
CD8+ T cells are negatively regulated by PD-1 and Tim-3
in human gastric cancer. Cell Immunol. 313:43–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
